Gilead Sciences Announces Price Tag For Coronavirus Drug Remdesivir

The transcript discusses the pricing and distribution of the antiviral drug Remdesivir by Gilead Sciences. It details the cost for US patients and compares it to prices in other developed countries. The CEO of Gilead Sciences highlights the drug's effectiveness in COVID-19 clinical trials and justifies its pricing. The Wall Street Journal projects significant sales and profits for Remdesivir. The drug has received FDA emergency use authorization and is administered through infusions. The Trump administration has secured a large number of treatment courses for American hospitals.

What new insight or understanding did you gain from this video?